Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine

Henrotin, Yves; Sanchez, Christelle; Cornet, A; Put, Joachim Van de; Douette, Pierre; Gharbi, Myriam

doi:10.3109/1354750x.2015.1123363

Cited by 15 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interleukins (IL-6, IL-8) and metalloproteases (MMP-3 and MMP-13) are some of the cytokines thought to be intimately related to degradation of type II collagen 1,5,6,28,29 . On average, OA becomes symptomatic and activity-prohibiting in patients 10 to 15 years after the initial traumatic event 12,14,16,18 . However, this degenerative process does not affect all patients with a history of ACL ruptures, as evidenced by the wide range of incidence in this population (0%-86%) [2][3][4][5][6][7] .…”

Section: Discussionmentioning

confidence: 99%

“…These biochemical markers of connective tissue are released into the systemic circulation and can be measured in blood, urine or synovial fluid. One of the main biomarkers for the diagnosis and prognosis of OA is C-telopeptide of type II collagen (CTX-II) [12][13][14][15][16][17] . This biomarker is released during the dynamic process of type II collagen degeneration, and consequently correlates with the destruction and formation of cartilage 13,[18][19][20][21][22][23][24][25][26] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of early degeneration of cartilage in patients with anterior cruciate ligament injuries: analysis using urine CTX-II biomarker

Nicolini

Mansur

Dreyfuss

et al. 2019

Preprint

View full text Add to dashboard Cite

Background:Anterior cruciate ligament (ACL) rupture occurs predominantly in young patients. About 30% of individuals with this lesion will present with osteoarthritis within 20 years following the trauma, despite successful treatment. This can be explained by metabolic changes occurring concomitantly with the trauma that results in the injury to this ligament. Using analysis of biomarkers related to cartilage degeneration, we aimed to determine that soon after the trauma leading to ACL rupture there are intra-articular metabolic changes in the knee that could lead to cartilage degeneration. Methods:A cross-sectional study was carried out in two groups: patients with an ACL ruptures and a control group (each group with ten male subjects, age range 18 – 35 years, body mass index below 30 kg/m2). In both groups, urine concentrations of a biomarker related to degradation of type II collagen (CTX-II) was measured. For the group with ACL rupture, a temporal relationship between time post-injury and amount of the biomarker was also examined. Results:There were significant differences in the concentrations of urinary CTX-II between the ACL group and the control group (p = 0.009). No significant relationship was observed between time of injury and the quantity of the biomarker. Conclusions:Patients with ACL injury had higher concentrations of urinary CTX-II biomarker than those with no ACL injury (p = 0.009). However, there was no correlation between the concentration of this biomarker and the elapsed time post-injury (p > 0.05). Keywords: osteoarthritis; biomarkers, ACL injury, CTX-II

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of early degeneration of cartilage in patients with anterior cruciate ligament injuries: analysis using urine CTX-II biomarker

Nicolini

Mansur

Dreyfuss

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Deberg [3] found that two kinds of degradation products of collagen type II collagen peptides: CTX II and PIIANP. Charni [4] found that the level of PIIANP in patients was significantly higher than that in healthy control group (Table 1). Double foot type of metabolic markers of bone, cartilage and synovial membrane.…”

Section: Introductionmentioning

confidence: 99%

“…When it is necessary to check the diagnosis of synovial fluid, X-ray changes could not explain the primary osteoarthritis. According to the development of OA, diagnosis and classification were carried out [4]. Therefore, the early diagnosis and treatment of osteoarthritis has important clinical significance.…”

Section: Introductionmentioning

confidence: 99%

Study on the clinical value of miRNA98b as a potential biomarker for osteoarthritis

Wang¹,

Ma²,

Xu³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

Objective: Osteoarthritis is a serious threat to the health of patients. Biomarkers have important significance in the diagnosis of bone arthritis. Bone mineral density is one of the important indicators for the detection of bone joint inflammation, but its detection is time-consuming and laborious. MicroRNA regulates cancer and inflammation. This study was to investigate the potential value of biomarkers miRNA98b in the diagnosis of early osteoarthritis. Methods: 69 cases of patients with osteoarthritis and 69 cases of healthy volunteers were regarded as research objects. Etidronate disodium had been continuously administrated for 4 w. The patient's bone density reached to the normal value which was regarded as effectiveness of the treatment. The miRNA98b level before and after therapy in blood cells of patients with osteoarthritis and healthy volunteers was detected by real time RT-PCR. The correlation between miRNA98b levels and osteoarthritis was analysed. Results: mRNA level of miRNA98b in blood cells of patients with osteoarthritis was higher than that of healthy volunteers. After being continuously administrated for 2 w, mRNA of miRNA98b in blood cells decreased, there was no significant change in the level of miRNA98b in blood cells of healthy volunteers. The level of miRNA98b in the blood cells of patients with severe osteoarthritis is higher than that in the blood cells of patients with general osteoarthritis, the difference was statistically significant (P<0.05). The level of miRNA98b in the blood cells of patients with osteoarthritis has a positive correlation with the severity of osteoarthritis. Conclusion: MiRNA98b in blood cells of patients with osteoarthritis may be a potential biomarker for osteoarthritis. The level of miRNA98b was correlated with the severity of osteoarthritis.

show abstract

“…Background: Coll2-1 is a nine amino acid sequence (HRGYPGLDG) specific of type II collagen which is released during cartilage degradation. This peptide is located in the triple helicoidal part of type II collagen molecule (1,2,3).…”

mentioning

confidence: 99%

Syndecan-4 Is Increased in Osteoarthritic Knee, but Not Hip or Shoulder, Articular Hypertrophic Chondrocytes

et al. 2019

Self Cite

View full text Add to dashboard Cite

Arthrocentesis was performed and sterile synovial fluid was found. Magnetic resonance images displayed a bone fragment detachment from the humeral condyle of the right elbow with synovium thickening and persistent effusion: the diagnosis of OCD was pointed out. The patient showed minor dysmorphisms (i.e. dolicocephaly, hypotelorism, arched palate and brachydactyly of the IV finger of both hands) and parents reported a previous episode of OCD when he was 12: at that time, symptoms resolved with non-weightbearing and non-steroidal anti-inflammatory therapy after few days. Furthermore, the patient went under regular endocrinologist follow-up for short stature since he was 8. At the age of 10, his height was 123 cm, SDS 2.4, and growth hormone (GH) stimulation tests showed partial response to insulin tolerance test (GH peak 6.27 ng/mL). Bone age at the X-Ray of right hand and wrist was delayed of 12 months. Human recombinant GH replacement therapy was administered without significant growth-velocity improvement. Although the patient came to observation because of suspected elbow septic arthritis, we re-considered the diagnosis: namely, i. recurrent episodes of OCD; ii. short stature that was poorly responsive to the human recombinant GH treatment, iii. mild skeletal and facial dysmorphisms, led us to hypothesize a form of aggrecanopathy. Molecular analysis of the ACAN gene revealed the novel missense variant c.6970T>C, p.Trp2324Arg in the G3 domain of the protein. Notably, another mutation of the G3 domain (c.7249G>A) has been previously related to aggrecanop-athy2. Intra-familial molecular analysis allowed us to detect the same gene variant in other three subjects (the mother and 2 siblings) affected only by brachydactily and short stature. Conclusion: A patient carrying a novel mutation of the ACAN gene presented an atypical form of aggrecanopathy mimicking inflammatory and/or septic arthritis associated with slight short stature and bone dysmorphisms. Further studies are needed to investigate a possible role of this novel ACAN gene variant in the inflammatory articular involvement.

show abstract

Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine

Cited by 15 publications

References 23 publications

Evaluation of early degeneration of cartilage in patients with anterior cruciate ligament injuries: analysis using urine CTX-II biomarker

Evaluation of early degeneration of cartilage in patients with anterior cruciate ligament injuries: analysis using urine CTX-II biomarker

Study on the clinical value of miRNA98b as a potential biomarker for osteoarthritis

Syndecan-4 Is Increased in Osteoarthritic Knee, but Not Hip or Shoulder, Articular Hypertrophic Chondrocytes

Contact Info

Product

Resources

About